Prolonged exposure to 5- ARIs does not impair detection of prostate cancer on MRI: Study
Prolonged exposure to 5-Alpha Reductase Inhibitors (5- ARIs) does not seem to weaken the detection of significant prostate cancer on MRI, suggests a study published in The Journal of Urology.
A group of researchers from Cleveland, Ohio, U.S.A. conducted a study to evaluate the influence of 5-ARIs on the performance of MRI for detection of Gleason grade group (GG) ≥2 prostate cancer, and on apparent diffusion coefficient (ADC) maps.
The researchers conducted this single-center, retrospective study wherein they included men who had MRI for initial detection or active surveillance of prostate cancer. The study group included a total of 59 men who used for 5-Alpha Reductase Inhibitors (5-ARIs) for ≥12 months, and the control group included a total of 59 men who were matched for both MRI indication and biopsy results. DeLong's test was used to compare the area under the receiver operating curve (AUC) for the detection of GG ≥2 cancer between the groups. Wilcoxon rank-sum test was used for comparison of lesions ADC metrics between the groups.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.